People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...
Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...
NAIROBI, Kenya, Feb 26 – Boehringer Ingelheim, the Germany-based research-driven biopharmaceutical company, has signed a Memorandum of Understanding (MoU) with Kenya’s Mission for Essential Drugs and ...
Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...
Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback